NASDAQ:TIL Instil Bio - TIL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.87 +0.05 (+6.12%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.81▼$0.8950-Day Range$0.48▼$1.4852-Week Range$0.47▼$13.01Volume1.51 million shsAverage Volume1.38 million shsMarket Capitalization$112.44 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Instil Bio MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside399.8% Upside$4.33 Price TargetShort InterestHealthy4.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.68) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector137th out of 1,053 stocksBiological Products, Except Diagnostic Industry25th out of 170 stocks 3.1 Analyst's Opinion Consensus RatingInstil Bio has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.33, Instil Bio has a forecasted upside of 399.8% from its current price of $0.87.Amount of Analyst CoverageInstil Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.50% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Instil Bio has recently decreased by 20.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInstil Bio does not currently pay a dividend.Dividend GrowthInstil Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TIL. Previous Next 3.0 News and Social Media Coverage News SentimentInstil Bio has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Instil Bio this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Instil Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Instil Bio insiders have not sold or bought any company stock.Percentage Held by Insiders51.50% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.87% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Instil Bio are expected to grow in the coming year, from ($1.68) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Instil Bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Instil Bio is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInstil Bio has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Instil Bio (NASDAQ:TIL) StockInstil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.Read More Receive TIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TIL Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comInstil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. SiteJanuary 24, 2023 | seekingalpha.comTIL Instil Bio, Inc.February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 9, 2023 | finance.yahoo.comInstil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal CancersJanuary 9, 2023 | finance.yahoo.comInstil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal CancerDecember 13, 2022 | finance.yahoo.comDown 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)December 12, 2022 | technews.tmcnet.comNewman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)December 12, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Instil BioFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 9, 2022 | finance.yahoo.comDown 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)December 8, 2022 | seekingalpha.comInstil Bio drops 11% as clinical priorities changeDecember 8, 2022 | finance.yahoo.comInstil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in WorkforceNovember 22, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Fox, Instil, Veru, and Twist and Encourages Investors to Contact the FirmNovember 17, 2022 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Instil BioNovember 17, 2022 | msn.comBaird Maintains Outperform Rating for Instil Bio: Here's What You Need To KnowNovember 17, 2022 | msn.com6 Analysts Have This to Say About Instil BioNovember 15, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILNovember 15, 2022 | finance.yahoo.comInstil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 8, 2022 | benzinga.comNationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Announces Investigation of Instil Bio, Inc. (TIL)November 8, 2022 | finance.yahoo.comInstil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 7, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Instil and Encourages Investors to Contact the FirmNovember 3, 2022 | benzinga.comInstil Bio, Inc. Investors: Please contact the Portnoy Law Firm to recover your lossesNovember 2, 2022 | apnews.comTIL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Instil Bio, Inc. Investors to Inquire About Securities Class Action Investigation – TILNovember 1, 2022 | seekingalpha.comInstil Bio slips 35% as manufacturing issue halts enrollment in trialsNovember 1, 2022 | benzinga.comEQUITY ALERT: Rosen Law Firm Encourages Instil Bio, Inc. Investors to Inquire About Securities Class Action Investigation – TILNovember 1, 2022 | marketwatch.comInstil Bio Shares Hit 52-Week Low After Pause in Enrollment for ITL-168 TrialNovember 1, 2022 | markets.businessinsider.comInstil Bio Plunges On Decision To Pause Enrollment For Clinical Trials Of ITIL-168 And ITIL-306See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TIL Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TIL CUSIPN/A CIK1625584 Webwww.tillcap.com Phone972-499-3350FaxN/AEmployees412Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.33 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+399.8%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-156,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.50% Return on Assets-39.48% Debt Debt-to-Equity Ratio0.15 Current Ratio7.45 Quick Ratio7.45 Sales & Book Value Annual Sales$140,000.00 Price / Sales803.15 Cash FlowN/A Price / Cash FlowN/A Book Value$4.31 per share Price / Book0.20Miscellaneous Outstanding Shares129,690,000Free Float62,902,000Market Cap$112.44 million OptionableNot Optionable Beta1.34 Key ExecutivesMr. Bronson Crouch (Age 50)Chairman & CEO Comp: $998.42kDr. Sandeep Laumas M.D. (Age 54)CFO & Chief Bus. Officer Dr. Mark E. Dudley Ph.D.Chief Scientific OfficerMs. Sumita Ray J.D. (Age 49)Chief Legal, Compliance, & Admin. Officer Dr. Robert Hawkins MBBSPh.D., Head of R&DKey CompetitorsCEL-SCINYSE:CVMGenenta ScienceNASDAQ:GNTABlack Diamond TherapeuticsNASDAQ:BDTXGamida CellNASDAQ:GMDAPrecision BioSciencesNASDAQ:DTILView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 50,321 shares on 12/8/2022Ownership: 0.189%M&T Bank CorpSold 10,430 shares on 11/17/2022Ownership: 0.070%Alliancebernstein L.P.Bought 8,600 shares on 11/15/2022Ownership: 0.157%Martingale Asset Management L PBought 6,172 shares on 11/15/2022Ownership: 0.015%Federated Hermes Inc.Bought 8,847 shares on 11/15/2022Ownership: 0.007%View All Institutional Transactions TIL Stock - Frequently Asked Questions Should I buy or sell Instil Bio stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Instil Bio in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TIL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TIL, but not buy additional shares or sell existing shares. View TIL analyst ratings or view top-rated stocks. What is Instil Bio's stock price forecast for 2023? 5 Wall Street research analysts have issued 12 month price objectives for Instil Bio's shares. Their TIL share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 399.8% from the stock's current price. View analysts price targets for TIL or view top-rated stocks among Wall Street analysts. How have TIL shares performed in 2023? Instil Bio's stock was trading at $0.63 at the start of the year. Since then, TIL stock has increased by 37.6% and is now trading at $0.8670. View the best growth stocks for 2023 here. Are investors shorting Instil Bio? Instil Bio saw a decrease in short interest in January. As of January 15th, there was short interest totaling 3,020,000 shares, a decrease of 20.1% from the December 31st total of 3,780,000 shares. Based on an average daily volume of 1,550,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 4.5% of the shares of the company are short sold. View Instil Bio's Short Interest. When is Instil Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023. View our TIL earnings forecast. How were Instil Bio's earnings last quarter? Instil Bio, Inc. (NASDAQ:TIL) announced its quarterly earnings results on Monday, November, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01. What other stocks do shareholders of Instil Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Instil Bio investors own include Bausch Health Companies (BHC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare Trust (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX), Yamana Gold (AUY), A. O. Smith (AOS), Sphere 3D (ANY) and Andersons (ANDE). When did Instil Bio IPO? (TIL) raised $250 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 13,900,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities served as the underwriters for the IPO. What is Instil Bio's stock symbol? Instil Bio trades on the NASDAQ under the ticker symbol "TIL." Who are Instil Bio's major shareholders? Instil Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include R Kent Mcgaughy Jr and Vivo Capital Ix, Llc. View institutional ownership trends. How do I buy shares of Instil Bio? Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Instil Bio's stock price today? One share of TIL stock can currently be purchased for approximately $0.87. How much money does Instil Bio make? Instil Bio (NASDAQ:TIL) has a market capitalization of $112.44 million and generates $140,000.00 in revenue each year. The company earns $-156,790,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis. How many employees does Instil Bio have? The company employs 412 workers across the globe. How can I contact Instil Bio? Instil Bio's mailing address is CONTINENTAL BUILDING 25 CHURCH STREET, HAMILTON D0, HM1Z. The official website for the company is www.tillcap.com. The company can be reached via phone at 972-499-3350 or via email at info@tillcap.com. This page (NASDAQ:TIL) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.